Global Trial in APG2575 for Patients With CLL/SLL

Part of paid clinical trials in Tuscon, Arizona.

Sponsor
Ascentage Pharma Group Inc.
Study ID
NCT06104566
Phase
PHASE3
Status
Recruiting

Conditions

  • CLL/SLL

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • lisaftoclax +BTK inhibitor — DRUG
    lisaftolax + BTK inhibitor
  • BTK inhibitor — DRUG
    BTK inhibitor

Study Details

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Key Dates

First listed
Oct 27, 2023
Start date
Dec 20, 2023
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Oct 31, 2027

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Arm 1
    Combination therapy
  • Active Comparator: Arm 2
    mono therapy

Primary Outcome Measure

PFS [ Time Frame: 12 months ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
Ascentage Investigative SiteTusconArizona85742-
Ascentage Investigative SiteAnaheimCalifornia92805-
Ascentage Investigative SiteJacksonvilleFlorida32224-
Ascentage Investigative SiteMiami BeachFlorida33140-
Ascentage Investigative SitePeoriaIllinois61615-
Ascentage Investigative SiteBostonMassachusetts02215-
Ascentage Investigative SiteAnn ArborMichigan48109-
Ascentage Investigative SiteGreenvilleNorth Carolina27834-
Ascentage Investigative SiteHoustonTexas77030
Nitin Jain, MD (PRINCIPAL_INVESTIGATOR)
Ascentage Investigative SiteKingswoodTexas77339-
Ascentage Investigative SiteRichmondVirginia23298-

Find similar trials in Tuscon, AZ

Related Studies